NEERVANNAN SESHA,WU KE,GORE ANURADHA V.,HOU HAO,PUJARA CHETAN P.
申请号：
CL2017000120
公开号：
CL2017000120A1
申请日:
2017.01.17
申请国别(地区):
CL
年份:
2017
代理人:
摘要：
<； p >； This Disclosure Bertalanffy refers to suspension formulations in Bertalanffy and Systems for the treatment of ocular disorders. The formulations in suspension Bertalanffy may include cyclosporine a and, in some ways, Form 1 or 2 of cyclosporine.It can provide a system of Administration, Bertalanffy includes two parts: a first part containing part & amp； cyclosporine particles and a second part which contains other components that can be combined with the first part to produce a Formulation in suspension & amp； n & amp； n.It is possible to inject the suspension & amp； n in the Subconjunctival space or other space periocular to treat Eye conditions, such as dry Eyes. <； / p >；una formulación en suspensión para inyección subconjuntival en el ojo de un ser humano que comprende ciclosporina, un agente de suspensión, un agente de osmolalidad, uno o más amortiguadores, un tensioactivo y un vehículo
